Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

Video

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Andre Goy, MD, Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology - Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University, Hackensack, NJ, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma (MCL).

In July 2020, the FDA approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus) to treat patients with relapsed/refractory MCL. The regulatory decision was based on findings from the phase 2 ZUMA-2 trial, in which a single infusion of the CAR T-cell product elicited an 87% objective response rate and a 62% complete response (CR) rate in this patient population.

The next steps with brexucabtagene autoleucel, as well as CAR T-cell therapy overall, is to improve responses for patients who do not achieve a CR, says Goy. Although the field is developing a greater understanding of how to mitigate the toxicities associated with CAR T-cell therapy, improvements in outcomes for patients with MCL, an aggressive lymphoma subtype, are still needed, Goy explains. Moreover, the concept of heavily pretreated patients and T-cell fitness as a mechanism that limits T-cell amplification could shed light on future research efforts, Goy says. Evaluating CAR T-cell therapy in a larger population of high-risk patients could highlight the widespread effect of this therapeutic modality in this setting, concludes Goy.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.